TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Final albuminuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bile duct cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dose-limiting toxicity (hypotension)
Endpoint domain: Adverse events/effects
Primary endpoint: HIVST kit use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Promotion of pupils' well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bioequivalence of selexipag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) for separating HFPEF from no HFPEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete eradication of all dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eradication of intestinal metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse clinical outcome (ARDS or death)
Endpoint domain: Mortality/survival
Primary endpoint: Improved blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated clotting time (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response criterion for BPRS (40% reduction in total score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGI-memory-scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events necessitating discontinuation of study anticoagulant
Endpoint domain: Adverse events/effects
Primary endpoint: Transfusion of red blood cell units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physical and mobility ICC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Personal care and instrumental ICC
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Applied cognition ICC
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of RDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TcPO2/FiO2 ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: right atrial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inhibition of itching and redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ITV D95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cord Dmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: skin texture improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean timed WMFT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posttreatment dexterity (NHPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total insulin requirement during the first 120 min after test-meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: airway opening pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: myocardial T1 time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: absolute LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse effects of treatments
Endpoint domain: Adverse events/effects
Primary endpoint: EAT Bulimia subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of food restraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pathologic body attitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in clinical and laboratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose to ipsi-lateral parotids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose to contra-lateral gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of improvement in leg vein sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure free survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: overall colonic transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 1,3‐beta‐D glucanase content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum aminotransferase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood ammonia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ROM of knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rehabilitation rate of knee joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of RNFLT and BMO-MRW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to manage stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total heparin administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-h blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: D-dimers at the end of operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cholesterol intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gingival recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum cotinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cytokine levels (IL-4, IL-5, IL-6, TNF-alpha, IFN-gamma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to fluid resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean audiometric hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival estimation accuracy
Endpoint domain: Mortality/survival
Primary endpoint: Experience of burdensome interventions
Endpoint domain: Adverse events/effects
Primary endpoint: PCR-corrected efficacy of ASAQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crude efficacy of ASAQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of new infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients who gained 3 lines or more of BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean foveal thickness (FTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in group mean composite symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to peak effect after bolus injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C50 values for loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bacterial abundance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: species richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: species diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Total cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Low-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Composite of death, recurrent myocardial infarction, myocardial ischemia, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Favourable outcome (GOC 3-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 2-h postprandial glucose (2-h PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24-h mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete tumor remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: sTNF-R1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma NE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Leptin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean pH of saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z score in lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Z score in femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of osteopenia and osteoporosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Freedom from perineal hernia at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean trunk sagittal acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEADL scale scores at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EQ-5D index scores at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HADS anxiety scale scores at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 14-day change in S5 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective curative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) annual rate of change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: total resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for subsequent interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gross arm activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak power output (W(peak))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak oxygen uptake (VO(2 peak))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak minute ventilation (VE(peak))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: UCVA of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HOA RMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: energy expenditure (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained and full PTSD remission
Endpoint domain: Mortality/survival
Primary endpoint: session-to-session PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cases of PTSD worsening
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy in motor learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variability in motor learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Time to Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No longer met diagnostic criteria for primary anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician ratings of impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report levels of overall anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous thromboembolic disease during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: mortality due to venous thromboembolic disease
Endpoint domain: Mortality/survival
Primary endpoint: clinically important bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: cerebral edema and ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: graft function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: chronic histopathology composite scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of emergent over‐selectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Morning PEF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Night PEF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Surgically induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidents of posterior capsular opaqueness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency and safety of tiotropium inhalation capsule in COPD treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Efficacy of EGFR inhibitory agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mammography use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: skin clearance response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in PASI from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: sPGA score ≤ 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HIV-RNA rebound in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-RNA rebound in seminal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-dose 3 seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: metabolic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P2X1/calponin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin preparation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic root diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Latent TGF‐β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP‐2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VLDL-TG 16:0/18:2n-6 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surface texture score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color match score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OIs (Opportunistic Infections)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood uric acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in MRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CGI-S score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in GAF score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoothness index for systolic and diastolic ambulatory blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of transfusions received
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of donor exposures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SANS anhedonia‐asociality subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social and Occupational Functioning Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Global Assessment of Functioning scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fever reaction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Strength increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracking error reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticospinal excitability increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Digit Span test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Social functioning domain of 36‐Item Short Form Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Wechsler Abbreviated Scale of Intelligence (WASI) for IQ verbal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in bladder diary end points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Smoking abstinence at 12 months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of postoperative pain
Endpoint domain: Adverse events/effects
Primary endpoint: Infant weight at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ponderal index at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived confidence of dietary change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin dose for blood sugar control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonatal blood sugar stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neonates NICU admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Bleeding on Probing Index (PBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Probing Pocket Depth (PPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: maximal power developed at the peak of the cyclergometer effort test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average time in hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: recurrence rates of pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: radiographic pleural adhesions appearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forward‐backward stability limits (maximal body lean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐confidence post intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastric erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes